Acadia Pharmaceuticals traded at $25.61 this Monday August 3rd, decreasing $0.26 or 1.01 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 0.62 percent. Over the last 12 months, its price rose by 6.53 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 25.32 by the end of this quarter and at 23.75 in one year, according to Trading Economics global macro models projections and analysts expectations.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).